345 related articles for article (PubMed ID: 22384806)
1. Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice.
Wang F; Wang Z; Tian H; Qi M; Zhai Z; Li S; Li R; Zhang H; Wang W; Fu S; Lu J; Rodriguez R; Guo Y; Zhou L
Curr Gene Ther; 2012 Apr; 12(2):67-76. PubMed ID: 22384806
[TBL] [Abstract][Full Text] [Related]
2. Teratogenic Toxicity Evaluation of Bladder Cancer-Specific Oncolytic Adenovirus on Mice.
Lu K; Wang F; Ma B; Cao W; Guo Q; Wang H; Rodriguez R; Wang Z
Curr Gene Ther; 2021; 21(2):160-166. PubMed ID: 33334289
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effects of bladder cancer-specific adenovirus carrying E1A-androgen receptor in bladder cancer.
Zhai Z; Wang Z; Fu S; Lu J; Wang F; Li R; Zhang H; Li S; Hou Z; Wang H; Rodriguez R
Gene Ther; 2012 Nov; 19(11):1065-74. PubMed ID: 22218302
[TBL] [Abstract][Full Text] [Related]
4. Combination of bladder cancer-specific oncolytic adenovirus gene therapy with cisplatin on bladder cancer in vitro.
Wang L; Zhang Y; Zhao J; Xiao E; Lu J; Fu S; Wang Z
Tumour Biol; 2014 Nov; 35(11):10879-90. PubMed ID: 25085582
[TBL] [Abstract][Full Text] [Related]
5. Construction of urothelium-specific recombinant adenovirus and its inhibition in bladder cancer cell.
He XD; Wang ZP; Wei HY; Zhou Q; Wang DG; Tian JQ; Fu SJ; Rodriguez R
Urol Int; 2009; 82(2):209-13. PubMed ID: 19322012
[TBL] [Abstract][Full Text] [Related]
6. HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.
Xu HN; Huang WD; Cai Y; Ding M; Gu JF; Wei N; Sun LY; Cao X; Li HG; Zhang KJ; Liu XR; Liu XY
Mol Cancer; 2011 Nov; 10():133. PubMed ID: 22040050
[TBL] [Abstract][Full Text] [Related]
7. Effect of combined treatment of radiation and tissue-specific recombinant oncolytic adenovirus on bladder cancer cells.
Zhang H; Wang F; Mao C; Zhang Z; Fu S; Lu J; Zhai Z; Li R; Li S; Rodriguez R; Wang Z
Int J Radiat Biol; 2017 Feb; 93(2):174-183. PubMed ID: 27600610
[TBL] [Abstract][Full Text] [Related]
8. The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus.
Xiao LL; Wu YM; Qian J; Tan Y; Xie GL; Zhang KJ; Wang YG; Jia XY; Liu XY
Cancer Biol Ther; 2010 Aug; 10(3):242-50. PubMed ID: 20574150
[TBL] [Abstract][Full Text] [Related]
9. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
[TBL] [Abstract][Full Text] [Related]
10. Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses.
Rojas JJ; Guedan S; Searle PF; Martinez-Quintanilla J; Gil-Hoyos R; Alcayaga-Miranda F; Cascallo M; Alemany R
Mol Ther; 2010 Nov; 18(11):1960-71. PubMed ID: 20808288
[TBL] [Abstract][Full Text] [Related]
11. Fusion of the BCL9 HD2 domain to E1A increases the cytopathic effect of an oncolytic adenovirus that targets colon cancer cells.
Fuerer C; Homicsko K; Lukashev AN; Pittet AL; Iggo RD
BMC Cancer; 2006 Oct; 6():236. PubMed ID: 17020613
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of tumor suppressor TSLC1 by a survivin-regulated oncolytic adenovirus significantly inhibits hepatocellular carcinoma growth.
He G; Lei W; Wang S; Xiao R; Guo K; Xia Y; Zhou X; Zhang K; Liu X; Wang Y
J Cancer Res Clin Oncol; 2012 Apr; 138(4):657-70. PubMed ID: 22237452
[TBL] [Abstract][Full Text] [Related]
13. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
14. Complete eradication of hepatomas using an oncolytic adenovirus containing AFP promoter controlling E1A and an E1B deletion to drive IL-24 expression.
Zhang KJ; Zhang J; Wu YM; Qian J; Liu XJ; Yan LC; Zhou XM; Xiao RJ; Wang YG; Cao X; Wei N; Liu XR; Tang B; Jiao XY; Chen K; Liu XY
Cancer Gene Ther; 2012 Sep; 19(9):619-29. PubMed ID: 22790965
[TBL] [Abstract][Full Text] [Related]
15. Tumor suppressor in lung cancer-1 (TSLC1) mediated by dual-regulated oncolytic adenovirus exerts specific antitumor actions in a mouse model.
Lei W; Liu HB; Wang SB; Zhou XM; Zheng SD; Guo KN; Ma BY; Xia YL; Tan WS; Liu XY; Wang YG
Acta Pharmacol Sin; 2013 Apr; 34(4):531-40. PubMed ID: 23503473
[TBL] [Abstract][Full Text] [Related]
16. Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT.
Doloff JC; Jounaidi Y; Waxman DJ
Cancer Gene Ther; 2011 Mar; 18(3):153-66. PubMed ID: 20865021
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic adenovirus armed with shRNA targeting MYCN gene inhibits neuroblastoma cell proliferation and in vivo xenograft tumor growth.
Li Y; Zhang B; Zhang H; Zhu X; Feng D; Zhang D; Zhuo B; Li L; Zheng J
J Cancer Res Clin Oncol; 2013 Jun; 139(6):933-41. PubMed ID: 23443256
[TBL] [Abstract][Full Text] [Related]
18. A novel bladder cancer - specific oncolytic adenovirus by CD46 and its effect combined with cisplatin against cancer cells of CAR negative expression.
Cao W; Tian J; Li C; Gao Y; Liu X; Lu J; Wang Y; Wang Z; Svatek RS; Rodriguez R
Virol J; 2017 Aug; 14(1):149. PubMed ID: 28789701
[TBL] [Abstract][Full Text] [Related]
19. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.
Zhang J; Lai W; Li Q; Yu Y; Jin J; Guo W; Zhou X; Liu X; Wang Y
Biochem Biophys Res Commun; 2017 Sep; 491(2):469-477. PubMed ID: 28698142
[TBL] [Abstract][Full Text] [Related]
20. Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel.
Zhang J; Ramesh N; Chen Y; Li Y; Dilley J; Working P; Yu DC
Cancer Res; 2002 Jul; 62(13):3743-50. PubMed ID: 12097284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
